The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Poly(ADP-ribose) polymerase 1 (PARP1) is an important component of the base excision repair (BER) pathway as well as a regulator of homologous recombination (HR) and nonhomologous end-joining (NHEJ). Previous studies have demonstrated that treatment of HR-deficient cells with PARP inhibitors results...
Main Authors: | Silvana eDe Lorenzo, Anand ePatel, Rachel eHurley, Scott H. Kaufmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00228/full |
Similar Items
-
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
by: Yongsong Wu, et al.
Published: (2023-01-01) -
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
by: Tao Xie, et al.
Published: (2022-09-01) -
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
by: Heng Zhu, et al.
Published: (2020-03-01) -
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
by: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Published: (2018-08-01) -
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
by: Stergios Boussios, et al.
Published: (2019-08-01)